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Abstract
Angiopoietin-like proteins (ANGPTL) are a family of several proteins, of which ANGPTL3, 4 and 8 are involved in lipid 
metabolism. These proteins, discovered relatively recently, regulate the availability of triglycerides for the heart, skeletal 
muscles and white and brown adipose tissue depending on the nutritional status of the body, thus contributing to the 
maintenance of energy homeostasis. ANGPTL3, 4 and 8 gene mutations are associated with a significant reduction in 
plasma lipid levels, which translates to a reduction in the risk of ischaemic heart disease and diabetes type 2. It was 
shown that blood levels of ANGPTL3, 4, 5 and 8 may change in various disease states, such as obesity or diabetes 
type 2, and thus may constitute biomarkers of the cardiovascular risk. Evinacumab, being a fully humanized anti-
-ANGPTL3 antibody, February, 11th, 2021, as Evkeeza® preparation, has been registered by the US Food and Drug Ad-
ministration for the treatment of homozygous familial hypercholesterolaemia. In clinical trials, evinacumab was charac-
terized by a high lipid-lowering efficacy in patients with homozygous and heterozygous familial hypercholesterolaemia, 
as well as treatment-resistant hypercholesterolaemia and hypertriglyceridaemia. Another drug that reduces ANGPTL3 
activity are antisense oligonucleotides targeting Angptl3 mRNA (ANGPTL3 ASO) which were also characterized by lipid 
lowering properties in clinical trials.
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Characteristics and role  
of angiopoetin-like proteins in the lipid  
and carbohydrate metabolism
Angiopoetin-like proteins (ANGPTL) are a group of proteins 
currently encompassing compounds ANGPTL1 through 
ANGPTL8 which belong to the family of vascular endothelial 
growth factor (VEGF). From the cardiovascular perspec-
tive, the important compounds are ANGPTL3, ANGPTL4 
and ANGPTL8, as they are involved in the metabolism of 
triglyceride-rich lipoproteins [1]. These proteins were di-
scovered in 1999, 2000, and 2012, respectively, and are 
characterized by a similar structure, with a fibrinogen-like 
C-terminal domain. The exception is ANGPTL8 which does 
not include this domain in its structure. The main sources 
of these proteins are the liver for ANGPTL3, the liver, 
adipose tissue, skeletal muscle, intestines, heart, and 
brain for ANGPTL4, and the liver and adipose tissue for 
ANGPTL8 [2, 3].
These proteins form a system that controls the avail-
ability of triglycerides depending on the current body nu-
trition status, temperature, and physical activity. Following 
a meal, triglycerides are stored in the white adipose tissue. 
During fasting, they become an energy substrate for the 
heart, skeletal muscle, and brown adipose tissue. Triglyc-
eride availability is regulated by lipoprotein lipase (LPL). 
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carbohydrate-responsive element-binding protein (ChREBP) 
in the regulation of Angptl8 expression [2, 4].
Thus, ANGPTL3, 4 and 8 play a major role in the lipo-
protein metabolism by regulating triglyceride hydrolysis 
depending on the body nutrition status. This mechanism 
is related to posttranslational LPL modification by these 
proteins.
These proteins, particularly ANGPTL4, also play a role 
in carbohydrate metabolism. Glucose tolerance improve-
ment and an increase in blood insulin level were shown 
in Angptl4 knockout (Angptl4–/–) mice [6]. These effects 
were likely related to the fact that an increase in LPL activ-
ity has a beneficial effect on the body energy homeostasis 
[7]. The role of ANGPTL3 in the carbohydrate metabolism is 
unclear and requires further studies [2]. A beneficial effect 
of ANGPTL8 on pancreatic beta cell proliferation was initial-
ly suggested, and the protein was named betatrophin but 
further studies did not confirm these observations [2, 8]. It 
should also be noted that these proteins also exert other met-
abolic effects that have often not been well characterized [9].
ANGPTL3, ANGPTL4 and ANGPTL8  
and cardiovascular risk
The interest in ANGPTL3, 4 and 8, in addition to their ef-
fect on metabolism, is related to the fact that mutations 
of genes coding for these proteins lead to significant 
Following a meal, LPL activity increases in the white adi-
pose tissue and decreases in the heart, skeletal muscle 
and brown adipose tissue, while during fasting, LPL activ-
ity increases in the heart, skeletal muscle and brown adi-
pose tissue, and decreases in the white adipose tissue [4]. 
Stimulation of LPL depends on ANGPTL3, 4 and 8. It was 
shown that ANGPTL3, ANGPTL4 and ANGPTL8 reduce LDL 
activity by changing its conformation from a homodimeric 
one (biologically active) to a monomeric one (biologically 
inactive), which is associated with a reduced LDL affinity to 
its stabilizing factor, glycosylphosphatidylinositol-anchored 
high-density lipoprotein binding protein 1 (GPIHBP1) [1]. In 
addition, ANGPTL3 reduces the activity of endothelial lipase 
(EL) [5] In the heart, skeletal muscle and brown adipose tis-
sue, postprandial LDL activity is reduced by ANGPTL3 and 
ANGPTL8 (ANGPTL8 expression is increased after a meal, 
while ANGPTL3 expression is not dependent on the nutrition 
status) that form a heterodimer (ANGPTL8 is an activator 
of ANGPTL3). In contrast, LPL activity in the white adipose 
tissue during fasting is decreased by ANGPTL4 (intracel-
lularly and extracellularly) (Figure 1) [1–5].
Factors stimulating ANGPTL3, 4 and 8 depending on 
the nutrition status have not been clearly identified. Pos-
tulated factors include a role of insulin and leptin in the 
regulation of ANGPTL3 expression, of glycocorticoste-
roids in the regulation of ANGPTL4 expression, and of ste-
rol regulatory element-binding protein 1c (SREBP1c) and 
Figure 1. Regulation of triglyceride metabolism by ANGPTL3, 4 and 8 (based on [1–5]); ANGPTL3, 4 and 8 — angiopoetin-like protein 3, 4 and 8; 
LPL — lipoprotein lipase; GPIHBP1 — glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1; FFA — free fatty acids; 
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disease and diabetes type 2. It was shown that the E40K 
ANGPTL4 gene mutation was associated by a 16% lower 
risk of ischaemic heart disease and a 12% lower risk of 
diabetes type 2 [14]. Gusarova et al. [15] in a study in 
more than 58,000 participants of the DiscovEHR Study 
also evaluated the effect of the E40K ANGPTL4 gene mu-
tation on the risk of diabetes type 2. Interestingly, this stu-
dy also showed that the risk of diabetes type 2 was 12% 
lower in the E40K ANGPTL4 gene mutation carriers. The 
authors concluded that this beneficial effect of the E40K 
ANGPTL4 gene mutation was due to lower fasting blood 
glucose levels and higher insulin sensitivity in the indivi-
duals carrying this mutation [15].
The effect of LOF ANGPTL8 gene mutations on the car-
diovascular risk was evaluated by Peloso et al. in a study 
in more than 56,000 individuals. The LOF ANGPTL8 gene 
mutation carriers were shown to have a 10 mg/dL lower 
plasma HDL level, and a 15% lower plasma triglyceride le-
vel. The effect of this mutation on plasma LDL level was 
not significant. Of interest, LOF ANGPTL8 gene mutation 
carriers were not found to have a lower risk of ischaemic 
heart disease [16].
Use of ANGPTL3, 4 and 8 as potential cardiovascular 
risk biomarkers was evaluated by Morinaga et al. in a cross-
-sectional study in 988 Japanese individuals. It was shown 
that serum ANGPTL3 level was relatively high in study par-
ticipants with liver dysfunction and inflammation, while se-
rum ANGPTL4 level was significantly elevated in case of im-
paired carbohydrate metabolism and liver failure but lower 
in inflammation. Finally, elevated serum ANGPTL8 level was 
seen in patients with obesity, impaired carbohydrate me-
tabolism, and dyslipidemia. In particular, elevated serum 
ANGPTL8 level showed a positive association with plasma 
triglyceride and LDL levels and a negative association with 
plasma HDL level. Thus, serum ANGPTL3, 4 and 8 levels 
may be helpful in the evaluation of cardiovascular risk [17].
In turn, Alghanim et al. [18] indicated a role for 
ANGPTL5 in the evaluation of cardiovascular risk in 2019. 
The study included 204 individuals, including 66% with 
obesity and/or diabetes type 2. Plasma ANGPTL5 level was 
found to be elevated in individuals with obesity and/or dia-
betes type 2. In addition, positive associations were found 
between plasma ANGPTL5 level and fasting blood gluco-
se level, haemoglobin A1c (HbA1c) level, plasma triglyceride 
level, and insulin resistance as evaluated by the homeo-
static model assessment — insulin resistance (HOMA-IR). 
From a clinical perspective, it should be noted that this 
study showed a gradual increase in plasma ANGPTL5 le-
vel in prediabetes [18].
In a recent study by Hammad et al. [19] in 431 adole-
scents, with more than 50% of them with an increased 
body weight, changes in ANGPTL5 level in relation to body 
weight were analysed. In addition, plasma high-sensitivity 
C-reactive protein (hsCRP) and oxidized LDL (ox-LDL) levels 
alterations of the lipid profile with resultant effects on the 
cardiovascular risk, and that blood levels of these proteins 
change in various diseases.
In the study by Sitiziel et al. [10], the effect of 
ANGPTL3 deficiency on the coronary atherosclerosis bur-
den and the risk of ischaemic heart disease was evaluated. 
In addition, this study evaluated the relationship between 
plasma ANGPTL3 level and the risk of myocardial infarc-
tion. In individuals with total ANGPTL3 deficiency, coronary 
atherosclerotic plaques were absent. The prevalence of 
heterozygous loss of function (LOF) Angptl3 gene mutation 
was 1:309. In heterozygous LOF Angptl3 gene mutation 
carriers, plasma total cholesterol, triglyceride, low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL) levels 
were reduced by 11%, 17%, 12%, and 5%, respectively, and 
these changes translated to a 34% lower risk of ischaemic 
heart disease. It was found that plasma ANGPTL3 level 
was related to the risk of myocardial infarction. Compared 
to individuals with higher plasma ANGPTL3 levels, those 
with plasma ANGPTL3 levels of 272–378 ng/mL and 18– 
–271 ng/mL were characterized by a 21% and 29% lower 
risk of myocardial infarction, respectively [10].
A similar study was performed by Dewey et al. [11]. In 
the study by these authors, ANGPTL3 gene exons were se-
quenced in nearly 60,000 participants of the DiscovEHR 
Study. This was followed by an analysis of the relation be-
tween the presence of normal ANGPTL3 gene or LOF mu-
tations of this gene and serum lipid levels [11].
It was found that the LOF ANGPTL3 gene mutation car-
riers were characterized by lower levels of the four major 
plasma lipid fractions, which translated to a 39% lower 
risk of ischaemic heart disease in these individuals [11].
In another study in more than 42,000 participants of 
the DiscovEHR Study, Dewey et al. [12] evaluated the re-
lation between inactivating ANGPTL4 gene mutations and 
plasma lipid levels and the risk of ischaemic heart disease. 
It was shown that inactivation of the ANGPTL4 gene was 
most commonly caused by a heterozygous E40K muta-
tion and resulted in a reduction in plasma total choleste-
rol, LDL, and triglyceride levels along with an increase in 
plasma HDL level [12].
Individuals with the E40K ANGPTL4 gene mutation 
(either heterozygous or homozygous) were characterized 
by a 19% lower risk of ischaemic heart disease. Other ina-
ctivating ANGPTL4 gene mutations led to insignificant re-
ductions of the ischaemic heart disease risk [12]. Similar 
results were obtained by Sitiziel et al. [13] in a study in 
nearly 194,000 individuals. These authors showed that 
E40K ANGPTL4 gene mutation carriers had a 35% lower 
plasma triglyceride levels and a 53% lower risk of ischae-
mic heart disease [13].
In an interesting study in more than 310,000 indi-
viduals, Klarin et al. [14] evaluated the effect of LOF 
ANGPTL4 gene mutations on the risk of ischaemic heart 
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were measured. ANGPTL5 level was found to be significantly 
increased in obese adolescents but it did not differ between 
normal body weight and overweight study participants [19].
In addition, plasma ANGPTL5 level showed a positi-
ve correlation with plasma hsCRP and ox-LDL levels [19].
Taking into account the results of other studies that 
showed that plasma ANGPTL3 and ANGPTL8 levels did 
not differ between normal body weight and obese adole-
scents [19–21], the study authors suggested that plasma 
ANGPTL5 level may be a specific biomarker of the cardio-
vascular risk in this age group [19].
Thus, it seems that ANGPTL5 secreted by the heart 
may play a yet unelucidated role in lipid metabolism [3].
In summary, LOF Angptl3, 4 and 8 gene mutations lead 
to lower plasma lipid levels. LOF Angptl3 and Angptl4 gene 
mutations are also associated with a significantly lower risk 
of ischaemic heart disease and diabetes type 2. In addi-
tion, changes in ANGPTL3, 4 and 8 levels may be biomar-
kers of the cardiovascular risk. ANGPTL5 also seems to be 
an interesting marker of the risk of carbohydrate metabo-
lism disturbances and the cardiovascular risk (particular-
ly in adolescents).
ANGPTL3, 4 and 8 as targets  
for drug therapy of cardiovascular disease
The interest in a major role of ANGPTL3, 4 and 8 in lipid 
metabolism led to the development of compounds that wo-
uld decrease the activity of these proteins. In experimental 
studies, use of a fully humanized antibody against ANGPTL4 
(REGN1001) significantly reduced plasma lipid levels and 
improved carbohydrate metabolism but was associated with 
mesenteric lymph node inflammation [12, 23–25], and use 
of a fully humanized antibody against ANGPTL8 (REGN3776) 
led to a decrease in plasma triglyceride level and body weight 
reduction [26]. However, as shown earlier, the lipid-lowering 
effect of reduced ANGPTL8 activity did not translate to an 
effect on the cardiovascular risk in humans [16].
Results of the clinical studies are available that evaluated 
a fully humanized antibody against ANGPTL3 (evinacumab) 
and antisense oligonucleotides targeting Angptl3 mRNA 
(ANGPTL3 ASO), administered in healthy volunteers and 
patients with lipid disorders.
Evinacumab
Evinacumab (RENG1500) is a fully humanized monoclonal 
antibody IgG4 against ANGPTL3 developed by Regene-
ron Pharmaceuticals, administered subcutaneously or 
intravenously [27]. Evinacumab, being a fully humanized 
anti-ANGPTL3 antibody, February, 11th, 2021, as Evkeeza® 
preparation, has been registered by the US Food and Drug 
Administration (FDA) for the treatment of homozygous 
familial hypercholesterolaemia (HoHF).
The mechanism of action of evinacumab involves redu-
cing the activity of circulating ANGPTL3 by forming a com-
plex with its molecule (Figure 2) [28].
Thus, indirect effects of the action of evinacumab in-
clude increased LPL and EL activity, reduced release of 
very low-density lipoproteins (VLDL), increased clearance 
of triglyceride-rich lipoproteins, and reduced lipolysis in the 
adipose tissue [29].
Figure 2. Mechanism of action of evinacumab and antisense oligonucleotides targeting Angptl3 mRNA (ANGPTL3-LRx) (based on [28]); 
ASGR — asialoglycoprotein receptor; ANGPTL3 — angiopoetin-like protein 3; mRNA — messenger RNA; ANGPTL3 ASO — antisense oligo-
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The first randomized, double-blind, placebo-controlled 
trial to evaluate the safety, activity profile and pharmaco-
kinetics of evinacumab was conducted by Dewey et al. 
This study included 83 healthy subjects with plasma trigly-
ceride level of 150–450 mg/dL and plasma LDL level of 
≥ 100 mg/dL. The study subjects were randomized to groups 
that received evinacumab intravenously (5, 10 or 20 mg/kg 
body weight), evinacumab subcutaneously (75, 150 or 
250 mg) or placebo. The most common adverse effect was 
headache (in 11% of the study subjects treated with evina-
cumab). There were no instances of evinacumab treatment 
withdrawal due to adverse effects. The maximum reduction 
in plasma triglyceride, LDL, and HDL levels, by 76% (day 4), 
23.2% (day 15) and 18.4% (day 15), respectively, was ob-
served in the group receiving evinacumab intravenously at 
the dose of 20 mg/kg body weight [11].
The safety, tolerance, pharmacokinetics, and potency of 
the lipid-lowering effect of evinacumab administered sub-
cutaneously or intravenously were also evaluated in a ran-
domized, double-blind, placebo controlled trial by Harada-
-Shiba et al. [30] in 96 healthy individuals with plasma LDL 
level of ≥2 .6 to < 4.1 mmol/L (≥ 100 to < 160 mg/dL). The 
study subjects were divided into 4 cohorts: I — 300 mg of 
evinacumab subcutaneously in a single dose; II — 5 mg/kg 
body weight of evinacumab intravenously, two doses 
4 weeks apart; III — 15 mg/kg body weight of evinacumab 
intravenously, two doses 4 weeks apart; and IV — 300 mg 
of evinacumab subcutaneously once a week for 8 weeks. 
Each cohort included 24 individuals (12 Japanese and 
12 Caucasians) who were randomized (3:1) to evinacumab 
or placebo. The duration of follow-up was 24 weeks. The 
safety profile of evinacumab (administered intravenously 
or subcutaneously) in both ethnic groups was shown to be 
comparable to placebo, without serious or severe adverse 
events. The pharmacokinetic profiles of evinacumab (ad-
ministered intravenously or subcutaneously) were compa-
rable between the study groups [30].
A dose-related decrease in plasma LDL, triglyceride, 
non-HDL, HDL, total cholesterol, apolipoprotein (apo) B, 
apo A-I, apo C-III, and lipoprotein(a) [Lp(a)] level was found. 
Administration of two evinacumab doses of 15 mg/kg 
body weight intravenously, 4 weeks apart, was charac-
terized by the highest potency of the lipid-lowering effect 
(reduction in plasma LDL, triglyceride, non-HDL, HDL, to-
tal cholesterol, apo B, apo A-I, apo C-III, and Lp(a) level at 
8 weeks by 40%, 63%, 44%, 24%, 41%, 30%, 41%, 78%, 
and 35%, respectively) [30].
Evinacumab in the treatment  
of homozygous familial  
hypercholesterolemia
The lipid-lowering efficacy of evinacumab in 9 patients 
with HoHF was evaluated by Gaudet et al. [31] Despite 
aggressive treatment used in the study subjects before 
recruitment to the trial [statins, ezetimibe, lomitapide, pro-
protein convertase subtilisin/kexin 9 (PCSK9) inhibitors], 
their mean plasma LDL level was 376 ± 240.9 mg/dL. The 
study subjects received evinacumab subcutaneously in 
a single 250 mg dose, followed by an intravenous dose of 
15 mg/kg body weight 2 weeks later. No serious adverse 
effects were observed during the 4-week follow-up. The 
mean reduction in triglyceride, LDL, HDL, non-HDL, and 
apo B level at 4 weeks was 47%, 49%, 36%, 49%, and 46%, 
respectively [31]. Of interest, an analysis of LDL receptor 
activity in lymphocytes harvested from these patients with 
HoHF showed that evinacumab reduced plasma LDL level 
via an LDL-receptor independent mechanism [32].
In the most recent double-blind placebo-controlled 
phase III trial (ELIPSE-HoHF Study), Raal et al. evaluated 
the therapeutic efficacy of evinacumab in 65 patients with 
HoHF. The study subjects were administered evinacumab 
15 mg/kg body weight intravenously every 4 weeks or 
placebo. The mean baseline plasma LDL (Figure 3), level 
was 255 mg/dL despite intensive lipid-lowering treatment. 
At 24 weeks, plasma LDL, total cholesterol, triglycerides, 
non-HDL, apo B, apo C-III, and Lp(a) level was noted to be 
significantly reduced by 47%, 47%, 55%, 50%, 41%, 84%, 
and 6%, respectively [33].
Of note, a reduction in plasma LDL by at least 50% was 
observed in 56% of the study subjects treated with evina-
cumab. At 24 weeks of evinacumab treatment, 28% of the 
patients had plasma LDL level below 70 mg/dL. The lipid-
-lowering efficacy of evinacumab was independent from 
the type of LDL receptor gene mutation (non/null or null/ 
/null). No serious adverse events were noted during evina-
cumab treatment [33].
Evinacumab in the treatment  
of heterozygous familial  
hypercholesterolaemia or treatment- 
-resistant hypercholesterolaemia
In a recently published double-blind, placebo-controlled pha-
se II trial, Rosenson et al. [34] evaluated the lipid-lowering 
efficacy of evinacumab in patients with heterozygous fami-
lial hypercholesterolaemia (HeHF) or treatment-resistant 
hypercholesterolaemia. The study included 272 patients, 
including 202 with HeHF. At baseline, all study subjects were 
on intensive lipid-lowering therapy, and the mean baseline 
plasma LDL level was 144–150 mg/dL. The patients were 
randomized to evinacumab intravenously (15 mg/kg bw 
every 4 weeks or 5 mg/kg bw every 4 weeks or placebo) 
or subcutaneously (450 mg once a week or 300 mg once 
a week or 300 mg once every two weeks or placebo). The du-
ration of follow-up was 16 weeks. During the study, the most 
common adverse effects in the subcutaneous evinacumab 
group included headache, erythema at the injection site, 
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nausea, sore throat, nasopharyngitis, back pain, urinary 
tract infection, and constipation, while the most common 
adverse effects in the intravenous subcutaneous evinacu-
mab group were: blood pressure elevation, nasopharyngitis, 
fatigue, muscle pain, and headache. A significant reduction 
in plasma LDL level was shown (Figure 4) [34].
Despite previous intensive lipid-lowering therapy, use 
of evinacumab in patients with HeHF and treatment-resi-
stant hypercholesterolaemia lead to plasma LDL reduction 
by another 50% [34].
Evinacumab in the treatment  
of hypertriglyceridaemia
Ahmad et al. conducted two phase I clinical trials to evalua-
te the safety and efficacy of evinacumab in the treatment of 
hypertriglyceridaemia. The studies included individuals with 
plasma triglyceride level > 150 to ≤ 450 mg/dL and plasma 
LDL level ≥ 100 mg/dL. The study with single increasing 
evinacumab doses (subcutaneous: 75, 150 or 250 mg; 
intravenous: 5, 10 or 20 mg/kg bw, or placebo) included 
83 patients who were followed up for 126 days. The study 
with multiple increasing evinacumab doses (subcutaneous: 
150, 300 or 450 mg once a week or 300/400 mg every 
2 weeks; intravenous: 20 mg/kg body weight every 4 weeks 
for 8 weeks) included 56 patients who were followed up 
for 6 months. Evinacumab was shown to be well tolerated. 
A significant reduction in plasma triglyceride level was 
noted (Figure 5) [35].
The maximum reduction in plasma triglyceride level 
with single increasing evinacumab doses was observed for 
the dose of 10 mg/kg body weight intravenously on Day 
3 (reduction by 76.9%), and with multiple increasing evina-
cumab doses for the dose of 20 mg/kg body weight intrave-
nously every 4 weeks on Day 2 (reduction by 83.1%) [35].
It was found that use of evinacumab resulted in a plas-
ma triglyceride level reduction comparable to that observed 
in individuals with LOF ANGPTL3 gene mutation [35].
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Figure 3. Change in plasma low-density lipoprotein (LDL) cholesterol levels in patients receiving placebo or intravenous evinacumab 15 mg/kg 
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Figure 5. Changes in plasma triglyceride level with single (A) or multiple (B) increasing evinacumab doses (based on Ahmad et al. [35]); 
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Currently, studies are underway that evaluate evina-
cumab treatment in patients with HoHF (NCT03409744, 
planned completion in 2022) and in children with 
HoHF (NCT04233918, planned completion in 2023). 
Another study has been completed that evaluated evi-
nacumab treatment in patients with severe hypertrigly-
ceridaemia and an increased risk of acute pancreati-
tis (NCT0345228) and a study evaluating the effect of 
evinacumab on lipid metabolism in adult patients with 
HoHF (NCT04722068).
Evkeeza®
As already mentioned, in February 2021 the FDA registered 
evinacumab known as Evkeeza® for the treatment of pa-
tients aged 12 years and older with HoHF. Recommended 
dose of the preparation is 15 mg/kg bw administered in-
travenously every 4 weeks. The drug infusion takes about 
60 min, while the lowering LDL cholesterol levels can be 
determined after 2 weeks from application. For the most 
common activities side effects of the drug include rhinitis 
and throat (16%), flu-like illness (7%), dizziness (6%), nasal 
discharge (5%) and nausea (5%) [36]. Expense annual 
treatment with Evkeeza® is approx 450 USD.
ANGPTL3 ASO
As shown in Figure 2, ANGPTL3 ASO interacts with the 
asialoglycoprotein receptor (ASGR), resulting in degrada-
tion of ANGPTL3 mRNA in hepatocytes. The overall effect 
of ANGPTL3 ASO administration is thus a reduction of 
ANGPTL3 production in hepatocytes (Figure 2) [28].
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The safety, pharmacokinetics, and ef ficacy of 
ANGPTL3 ASO were evaluated by Graham et al. in 44 in-
dividuals with plasma triglyceride level of 90–150 mg/dL 
or > 150 mg/dL. The study subjects were randomized to 
subcutaneous injections of ANGPTL3 ASO or placebo in 
a single dose (20, 40 or 80 mg) or multiple doses (10, 20, 
40 or 60 mg once a week for 6 weeks). No serious adver-
se events were reported during the study (most commonly 
reported adverse effects were dizziness and headache). 
A reduction in plasma ANGPTL3 and lipid levels was no-
ted (Figure 6) [36].
Administration of ANGPTL3 ASO resulted in a reduc-
tion of the plasma level of atherogenic lipoproteins [36].
Studies have been completed that evaluated ANGPTL3 
ASO (ISIS 703802) in the treatment of familial partial 
lipodystrophy (NCT03514420) and familial chylomicronae-
mia (NCT03360747) and in the treatment of patients with 
hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty 
liver disease (NCT03371355).
Summary
Angiopoetin-like proteins do not currently have an estab-
lished therapeutic role in the management of hyperchole-
sterolaemia, diabetes, and obesity, and we are still lacking 
complete pathophysiological data that would allow a clear 
definition of their role in the cardiovascular disease [38]. 
Paradoxically, however, a rapid and satisfactory clinical trial 
program of the new monoclonal antibody (evinacumab) de-
veloped by a leading pharmaceutical company Regeneron, 
Figure 6. Changes in plasma angiopoetin-like protein 3 (ANGPTL3) and lipid levels during treatment with multiple (A) or single (B) ANGPTL3 
ASO injections (based on Graham et al. [36]); TG — triglycerides; LDL — low-density lipoproteins; VLDL — very low-density lipoproteins; 
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with the availability of this drug on the market from February 
2021, allow us to summarize the current knowledge about 
these proteins in the following way:
 — ANGPTL3, 4 and 8 seem to play a major role in lipid 
metabolism by regulating triglyceride availability for the 
heart, skeletal muscle, and white and brown adipose 
tissue in relation to the body nutrition status;
 — changes in plasma ANGPTL3, 4, 5 and 8 levels may be 
cardiovascular risk markers;
 — evinacumab, a fully humanized antibody against 
ANGPTL3, has been characterized by a good tolerance 
and potent lipid-lowering properties in the studies in 
patients with HoHF, HeHF, treatment-resistant hyper-
cholesterolaemia and hypertriglyceridaemia and will 
be soon available clinically;
 — evinacumab in the form of Evkeeza® stayed in Febru-
ary 2021 registered by the FDA for treatment HoHF in 
people aged 12 years and older;
 — more studies on evinacumab and further drugs of 
this class are required, in particular regarding head-
-to-head comparisons and combination therapy with 
PCSK9 inhibitors;
 — drugs of this class may also represent the long-awaited 
advance in the management of hypertriglyceridemia as 
add-ons to omega-3 fatty acids and fibrates.
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